IgA Nephropathy Clinical Trial Landscape Intensifies With 25+ Companies and 30+ Pipeline Drugs in Active Development | DelveInsight

The IgA nephropathy clinical trial landscape features more than 30 pipeline therapies across multiple stages of development, with leading companies advancing complement inhibitors, APRIL/BAFF antagonists, CD38-targeted therapies, RNA interference approaches, and other novel mechanisms.

DelveInsight's latest IgA Nephropathy Pipeline Insight 2026 report highlights a rapidly evolving treatment landscape, with more than 25 active companies developing over 30 pipeline drugs for immunoglobulin A nephropathy (IgAN). The report provides comprehensive insights into ongoing clinical trials, emerging therapies, clinical development strategies, competitive dynamics, regulatory milestones, and commercial opportunities shaping the IgAN market.

DelveInsight's IgA Nephropathy Pipeline Insight 2026 report provides global coverage of pipeline therapies across discovery, preclinical, Phase I, Phase II, and Phase III development. The analysis evaluates key clinical trends, emerging treatment approaches, clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving major agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).

IgA Nephropathy Clinical Trial Analysis: Key Highlights

• More than 25 companies are actively developing 30+ pipeline therapies for IgA nephropathy.

• Approximately 12+ IgA nephropathy therapies are in late-stage development, including several Phase III candidates.

• Key companies involved in IgAN drug development include Haisco Pharmaceutical Group, Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca/Alexion Pharmaceuticals, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, Keymed Biosciences, Nanjing Chia-tai Tianqing Pharmaceutical, Rona Therapeutics, Infinimmune, and others.

• Promising pipeline therapies include HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS (ravulizumab), Sefaxersen, TAK-079 (mezagitamab), ARO-C3, NM8074 (ruxoprubart), WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, IFX 301, and others.

• Leading mechanisms of action under investigation include Complement Factor B inhibition, BAFF/APRIL antagonism, anti-APRIL targeting, antibody-dependent cellular cytotoxicity, Gd-IgA1 degradation, RNA interference, and CD38 targeting.

• Emerging therapies are being evaluated through different routes of administration, including oral and subcutaneous delivery.

Request a sample and discover the latest advances in IgA nephropathy drug development:
https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

What Is IgA Nephropathy?

IgA nephropathy, also known as Berger's disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, the tiny filtering structures responsible for filtering waste from the blood. The accumulation of IgA can trigger inflammation and progressively affect kidney function.

Patients may experience symptoms such as hematuria, proteinuria, high blood pressure, and swelling. Disease severity can vary considerably, with some patients experiencing a relatively stable course while others may progress to chronic kidney disease or kidney failure. Early diagnosis and appropriate disease management are important for preserving kidney function and slowing disease progression.

Learn more about IgA nephropathy drug development @ IgA Nephropathy Treatment

Snapshot of Pipeline IgA Nephropathy Drugs

• HSK39297 – Haisco Pharmaceutical Group Co., Ltd. | Phase III | Complement Factor B inhibitor | Oral

• Povetacicept – Vertex Pharmaceuticals | Phase III | BAFF and APRIL antagonist | Subcutaneous

• Zigakibart – Novartis AG | Phase III | Anti-APRIL | Subcutaneous

• CM313 – Keymed Biosciences Co., Ltd. / Timberley Therapeutics | Phase II | CD38 antagonist | Subcutaneous

• NTQ5082 – Nanjing Chia-tai Tianqing Pharmaceutical | Phase II | Complement Factor B inhibitor | Oral

• BHV-1400 – Biohaven, Ltd. | Phase I | Galactosyl-deficient IgA1 degrader | Subcutaneous

• RNK288 – Rona Therapeutics | Preclinical | RNA interference | Not applicable

• IFX 301 – Infinimmune | Preclinical | APRIL modulator | Not applicable

Learn more about emerging IgA nephropathy therapies @ IgA Nephropathy Clinical Trials

Analyst Perspective on the IgA Nephropathy Treatment Landscape

According to Stuti Mahajan, Consulting Manager at DelveInsight, the IgA nephropathy treatment landscape is entering a transformative phase as targeted therapies increasingly focus on the underlying biological drivers of the disease.

Therapies such as povetacicept and zigakibart, which target the APRIL/BAFF pathway, together with complement inhibitors such as HSK39297 and innovative approaches such as BHV-1400, could broaden treatment options for patients with IgAN.

These next-generation approaches are being developed with the potential to reduce proteinuria, slow disease progression, reduce dependence on corticosteroid-based treatment, and enable more personalized treatment strategies. The IgAN landscape is expected to increasingly move toward targeted therapies, combination approaches, precision medicine, and earlier intervention.

Recent Developments in the IgA Nephropathy Treatment Space

• In May 2026: Vor Bio announced that results from the Phase III TELIGAN trial evaluating telitacicept in IgA nephropathy in China, sponsored by its collaborator RemeGen Co., Ltd., were published in The New England Journal of Medicine.

• In March 2026: Vertex Pharmaceuticals announced positive data from a prespecified Week 36 interim analysis of the ongoing Phase III RAINIER trial evaluating povetacicept in IgA nephropathy.

• In November 2025: Vertex Pharmaceuticals reported updated Phase I/II data from the RUBY-3 study at the American Society of Nephrology Kidney Week.

• In November 2025: Vera Therapeutics reported positive Phase III ORIGIN data for atacicept in IgA nephropathy, with results presented at ASN Kidney Week 2025 and published in The New England Journal of Medicine.

• In November 2025: Takeda Pharmaceutical reported data showing sustained preservation of kidney function up to 18 months following treatment with mezagitamab (TAK-079) in patients with primary IgA nephropathy.

• In November 2025: Jade Biosciences presented two posters for JADE101, its investigational anti-APRIL monoclonal antibody, at ASN Kidney Week 2025.

• In September 2025: Walden Biosciences reported progress supporting the development of WAL0921, including advancement of its ongoing Phase II basket study and regulatory planning activities.

Scope of the IgA Nephropathy Pipeline Report

• Coverage: Global

• Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Clinical Development Stages: Discovery, Preclinical, Phase I, Phase II, Phase III

• Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal

• Molecule Type: Oligonucleotide, Peptide, Small Molecule

• Mechanism of Action: Complement Factor B inhibitor, BAFF/APRIL antagonist, antibody-dependent cellular cytotoxicity, Gd-IgA1 degrader, RNA interference, CD38 antagonist, and others

• Key IgA Nephropathy Companies: Eucure (Beijing) Biopharma Co., Ltd., Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca/Alexion Pharmaceuticals, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, Nanjing Chia-tai Tianqing Pharmaceutical, Keymed Biosciences Co., Ltd., Rona Therapeutics, Infinimmune, and others.

• Key IgA Nephropathy Pipeline Therapies: HSK39297, Zigakibart, Povetacicept, Felzartamab, Atacicept, ULTOMIRIS (ravulizumab), Sefaxersen, TAK-079 (mezagitamab), ARO-C3, NM8074 (ruxoprubart), WAL0921, KP104, PS-002, BHV-1400, CM313, NTQ5082, RNK288, IFX 301, and others.

Dive deep into rich insights for new IgA nephropathy treatments, visit @ IgA Nephropathy Drugs

Table of Contents

1. Introduction

2. Executive Summary

3. IgA Nephropathy: Overview

4. Pipeline Therapeutics

5. Comparative Analysis

6. Therapeutic Assessment

7. IgA Nephropathy – DelveInsight’s Analytical Perspective

8. Late Stage Products (Phase III)

9. Mid Stage Products (Phase II)

10. Early Stage Products (Phase I/II)

11. Preclinical and Discovery Stage Products

12. Inactive Products

13. IgA Nephropathy Key Companies

14. IgA Nephropathy Key Products

15. IgA Nephropathy - Unmet Needs

16. IgA Nephropathy - Market Drivers and Barriers

17. IgA Nephropathy - Future Perspectives and Conclusion

18. IgA Nephropathy Analyst Views

19. Appendix

For further information on the IgA nephropathy cure research, reach out @ Medication for IgA Nephropathy Treatment

Related Reports

IgA Nephropathy Market

DelveInsight's IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2036 report provides an in-depth assessment of disease epidemiology, market trends, market drivers and barriers, and the competitive landscape. Key companies covered include Novartis, Vertex Pharmaceuticals, Biogen, Vera Therapeutics, AstraZeneca/Alexion Pharmaceuticals, F. Hoffmann-La Roche, Ionis Pharmaceuticals, Takeda Pharmaceutical, Arrowhead Pharmaceuticals, NovelMed, Walden Biosciences, Kira Pharmaceuticals, Purespring Therapeutics, Biohaven Therapeutics, and others.

Acute Kidney Injury Clinical Trial Analysis

DelveInsight's Acute Kidney Injury Pipeline Insight – 2026 report provides comprehensive insights into the AKI pipeline landscape, including clinical and non-clinical stage products and key companies involved in developing novel therapies.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market research, consulting, competitive intelligence, and commercial strategy solutions to help pharmaceutical and biotechnology companies make informed business decisions.

DelveInsight also provides access to healthcare and pharmaceutical market research reports through its subscription-based platform, PharmDelve.

Contact Us

Kanishk 

info@delveinsight.com 

Polycythemia Vera Market: Growth Momentum Across 7MM to 2034 – DelveInsight

The Polycythemia Vera market is expected to experience continued growth as increasing disease awareness, evolving treatment approaches, and the development of novel therapies create new opportunities. Emerging treatments such as rusfertide, givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003 are expected to influence the future treatment landscape.

LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- DelveInsight's recently published “Polycythemia Vera Market Insights, Epidemiology, and Market Forecast-2034” report provides a comprehensive assessment of the Polycythemia Vera market, including current treatment practices, emerging therapies, epidemiology, market trends, and forecasted market size across the seven major markets (7MM): the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Polycythemia Vera Market Summary

• According to DelveInsight's analysis, the Polycythemia Vera market size was approximately USD 1.9 billion in the 7MM in 2024 and is anticipated to grow during the forecast period (2020–2034).

• The United States accounted for the highest number of Polycythemia Vera cases among the 7MM in 2023, with approximately 180,000 prevalent cases.

• In the EU4 and the United Kingdom, Germany had the highest number of Polycythemia Vera cases, with nearly 25,000 cases in 2023, while Spain reported the lowest number of cases.

• According to Orphanet, Polycythemia Vera affects approximately 30 individuals per 100,000 people in Germany, translating to nearly 24,000 affected individuals when extrapolated to the country's population.

• Several emerging therapies are expected to influence the Polycythemia Vera treatment landscape, including rusfertide (PTG-300), givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003.

• Key companies involved in Polycythemia Vera drug development include Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals, Incyte Corporation, and others.

• The Polycythemia Vera market is expected to benefit from the development of novel therapies targeting disease biology and treatment-related challenges.

Get a Free Sample for the Polycythemia Vera Market Report @
Polycythemia Vera Market Report

Key Factors Driving the Growth of the Polycythemia Vera Market

Rising Disease Burden

Polycythemia Vera continues to represent an important hematological disorder within the myeloproliferative neoplasm landscape. The United States had the highest number of cases among the 7MM in 2023, while Germany represented the leading country within the EU4 and the United Kingdom.

The continued identification and diagnosis of patients, together with growing disease awareness, are expected to support demand for effective long-term treatment options.

Increasing Focus on Novel Treatment Approaches

The Polycythemia Vera treatment landscape is gradually moving toward therapies that can address important disease-management challenges. Existing treatments may not be suitable or sufficiently effective for every patient, creating opportunities for novel mechanisms of action.

According to Kuykendall (2023), up to 25% of patients may develop resistance to or intolerance of hydroxyurea, highlighting an important unmet need and supporting continued research into alternative treatment strategies.

Development of Emerging Therapies

The Polycythemia Vera market is expected to become increasingly competitive as pipeline therapies progress through clinical development. Candidates such as rusfertide, givinostat, bomedemstat, SLN124, sapablursen, and PPMX-T003 are being evaluated for their potential to address important treatment gaps.

Polycythemia Vera Market Analysis

The Polycythemia Vera market is undergoing a period of therapeutic development, supported by advances in understanding disease biology and increasing investment in targeted treatment approaches.

Rusfertide, developed by Protagonist Therapeutics, represents one of the most closely watched emerging therapies in the Polycythemia Vera pipeline. The investigational therapy is a hepcidin mimetic designed to help manage erythrocytosis and reduce the need for frequent phlebotomy.

In January 2026, a New Drug Application (NDA) was filed with the U.S. FDA for rusfertide for the treatment of adults with Polycythemia Vera. The submission was supported by findings from the Phase III VERIFY trial and the Phase II REVIVE trial. The VERIFY study evaluated rusfertide in combination with standard of care and reported positive results across its primary and key secondary endpoints.

The competitive landscape is also being influenced by other emerging therapies. Givinostat, developed by Italfarmaco, received FDA Fast Track designation in May 2025 for Polycythemia Vera. Meanwhile, VGT-1849B, a JAK2 inhibitor developed by Vanda Pharmaceuticals, received FDA Orphan Drug Designation in August 2025 for the treatment of Polycythemia Vera.

These developments highlight the growing focus on therapies with differentiated mechanisms and the potential to improve disease control.

Polycythemia Vera Competitive Landscape

Some of the key companies developing or evaluating therapies for Polycythemia Vera include Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others.

Rusfertide (PTG-300): Protagonist Therapeutics

Rusfertide is an investigational hepcidin mimetic peptide designed to address erythrocytosis in patients with Polycythemia Vera. Its development is focused on improving hematocrit control and reducing the burden associated with phlebotomy.

In August 2025, the FDA granted Breakthrough Therapy Designation to rusfertide for the treatment of erythrocytosis in Polycythemia Vera patients with limited therapeutic options.

Givinostat (ITF2357): Italfarmaco

Givinostat is an investigational therapy being evaluated for Polycythemia Vera. In May 2025, the FDA granted Fast Track designation to givinostat for the indication, supporting its continued development in the Polycythemia Vera treatment landscape.

Bomedemstat: Imago BioSciences

Bomedemstat is another emerging therapy being evaluated for Polycythemia Vera. Its development reflects the increasing focus on novel approaches that may address the underlying biology of myeloproliferative neoplasms.

SLN124: Silence Therapeutics

Silence Therapeutics is developing SLN124, an siRNA-based therapeutic approach targeting pathways relevant to Polycythemia Vera. Additional clinical findings from the SANRECO study have contributed to the evolving understanding of RNA-based approaches in the disease.

Sapablursen: Ionis Pharmaceutical

Ionis Pharmaceutical is developing sapablursen, another investigational candidate being evaluated as part of the broader pipeline of emerging Polycythemia Vera therapies.

PPMX-T003: Perseus Proteomics

PPMX-T003 is an emerging therapeutic candidate being evaluated for Polycythemia Vera, further contributing to the competitive pipeline and diversification of potential treatment mechanisms.

Discover more about the emerging Polycythemia Vera therapies @
Polycythemia Vera Treatment Market

Recent Developments in the Polycythemia Vera Market

• January 2026: A New Drug Application was filed with the FDA for rusfertide for the treatment of adults with Polycythemia Vera. The submission was supported by results from the Phase III VERIFY and Phase II REVIVE studies.

• November 2025: SOTIO Biotech announced preclinical findings for SOT106 at the Connective Tissue Oncology Society Annual Meeting.

• August 2025: The FDA granted Breakthrough Therapy Designation to rusfertide for the treatment of erythrocytosis in Polycythemia Vera.

• August 2025: Vanda Pharmaceuticals announced that VGT-1849B received FDA Orphan Drug Designation for Polycythemia Vera.

• May 2025: The FDA granted Fast Track designation to givinostat for the treatment of Polycythemia Vera.

• March 2025: Protagonist Therapeutics and Takeda announced positive topline results from the Phase III VERIFY study of rusfertide.

• December 2024: Silence Therapeutics announced additional results from the Phase I open-label segment of the SANRECO study evaluating divesiran in patients with Polycythemia Vera.

• June 2024: AOP Health presented updated findings from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b.

• February 2024: Disc Medicine announced that the FDA granted Orphan Drug Designation to DISC-3405 for the treatment of Polycythemia Vera.

• January 2024: Takeda and Protagonist Therapeutics established a global licensing and collaboration agreement for rusfertide.

What is Polycythemia Vera?

Polycythemia Vera (PV) is a rare, chronic blood disorder characterized by the abnormal overproduction of blood cells, particularly red blood cells, in the bone marrow. The resulting increase in blood cell concentration can make the blood thicker and increase the risk of complications such as blood clots.

Polycythemia Vera belongs to a group of blood cancers known as myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of blood cells. Long-term disease management focuses on controlling blood counts and reducing the risk of complications.

To know more about the Polycythemia Vera market outlook, drug uptake, treatment scenario, and epidemiology trends @ Polycythemia Vera Market Forecast

Polycythemia Vera Epidemiology

The Polycythemia Vera epidemiology section provides historical, current, and forecasted epidemiological insights across the 7MM during the study period 2020–2034.

In 2023, the United States had approximately 180,000 prevalent Polycythemia Vera cases, representing the largest patient population among the seven major markets.

Within the EU4 and the United Kingdom, Germany had the highest number of cases, with nearly 25,000 cases in 2023.

The Polycythemia Vera epidemiology analysis is segmented into:

• Total Prevalence of Polycythemia Vera

• Prevalent Cases of Polycythemia Vera by Severity

• Gender-specific Prevalence of Polycythemia Vera

• Diagnosed Cases of Episodic and Chronic Polycythemia Vera

Download the report to understand Polycythemia Vera epidemiology trends @ Polycythemia Vera Epidemiology Forecast

Polycythemia Vera Drugs Uptake and Pipeline Development Activities

The drug uptake section of the report evaluates the expected adoption of recently launched and emerging therapies during the forecast period. The analysis includes drug-specific market uptake, patient uptake, sales, and market share.

The report also provides an assessment of the Polycythemia Vera pipeline, covering therapies across different stages of clinical development and the companies responsible for their development.

In addition, the pipeline analysis examines important industry developments, including collaborations, licensing agreements, acquisitions, mergers, patent information, and other strategic activities that may influence the market.

Polycythemia Vera Therapies and Key Companies

• Rusfertide (PTG-300): Protagonist Therapeutics

• Givinostat (ITF2357): Italfarmaco

• Bomedemstat: Imago BioSciences

• SLN124: Silence Therapeutics

• Sapablursen: Ionis Pharmaceutical

• PPMX-T003: Perseus Proteomics

• PTG-300: Protagonist Therapeutics, Inc.

• SLN124: Silence Therapeutics plc

• Hydroxyurea: Novartis

• Ropeginterferon alfa-2b: PharmaEssentia

• PEG-P-INF alpha-2b (P1101): AOP Orphan Pharmaceuticals AG

• Ruxolitinib: Incyte Corporation

Discover more about therapies expected to capture Polycythemia Vera market share @ Polycythemia Vera Treatment Market

Polycythemia Vera Market Strengths

• The approval of BESREMi in the United States and its potential expansion across additional treatment settings provide an opportunity for interferon-based therapy to strengthen its position in the Polycythemia Vera market.

• Increasing adoption of JAKAFI/JAKAVI supports its potential to remain an important therapy for patients requiring second-line treatment.

Polycythemia Vera Market Opportunities

• Increasing strategic alliances, including geographical partnerships and licensing agreements, may support the development and commercialization of emerging therapies.

• FDA designations such as Breakthrough Therapy Designation and Fast Track designation can support accelerated development pathways for promising candidates.

• Novel therapies with differentiated or disease-modifying mechanisms and improved tolerability may address important unmet needs in Polycythemia Vera.

Scope of the Polycythemia Vera Market Report

• Study Period: 2020–2034

• Coverage: 7MM 

• Key Polycythemia Vera Companies: Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharmaceutical, Perseus Proteomics, Novartis, PharmaEssentia, AOP Orphan Pharmaceuticals AG, Incyte Corporation, and others

• Key Polycythemia Vera Therapies: Rusfertide (PTG-300), Givinostat (ITF2357), Bomedemstat, SLN124, Sapablursen, PPMX-T003, Hydroxyurea, Ropeginterferon alfa-2b, PEG-P-INF alpha-2b (P1101), Ruxolitinib, and others

• Polycythemia Vera Therapeutic Assessment: Current marketed and emerging therapies

• Polycythemia Vera Market Dynamics: Market drivers and market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's Five Forces, BCG Matrix, and market entry strategies

• Unmet Needs: KOL views, analyst views, market access, and reimbursement

To learn more about companies working in the Polycythemia Vera treatment market @ Polycythemia Vera Clinical Trials and Therapeutic Assessment

Table of Contents

1. Polycythemia Vera Market Report Introduction

2. Executive Summary for Polycythemia Vera

3. SWOT Analysis of Polycythemia Vera

4. Polycythemia Vera Patient Share (%) Overview at a Glance

5. Polycythemia Vera Market Overview at a Glance

6. Polycythemia Vera Disease Background and Overview

7. Polycythemia Vera Epidemiology and Patient Population

8. Country-Specific Patient Population of Polycythemia Vera

9. Polycythemia Vera Current Treatment and Medical Practices

10. Polycythemia Vera Unmet Needs

11. Polycythemia Vera Emerging Therapies

12. Polycythemia Vera Market Outlook

13. Country-Wise Polycythemia Vera Market Analysis (2020–2034)

14. Polycythemia Vera Market Access and Reimbursement of Therapies

15. Polycythemia Vera Market Drivers

16. Polycythemia Vera Market Barriers

17. Polycythemia Vera Appendix

18. Polycythemia Vera Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on the life sciences industry. It supports pharma companies by providing comprehensive end-to-end solutions designed to improve business performance.

DelveInsight also offers Healthcare Consulting Services, supporting market analysis, strategic decision-making, and business growth while helping organizations address complex challenges with a practical and data-driven approach.

Contact Us

Kanishk

info@delveinsight.com 

Eosinophilic Esophagitis Pipeline Shows Strong Momentum as 25+ Pharma Companies Compete in Drug Development | DelveInsight

DelveInsight’s latest “Eosinophilic Esophagitis Pipeline Insights 2026” report provides a comprehensive assessment of the evolving Eosinophilic Esophagitis (EoE) pipeline, covering 25+ companies and 30+ pipeline therapies across clinical and preclinical development stages.

The report offers detailed insights into emerging EoE drugs, key companies, clinical development stages, mechanisms of action, routes of administration, molecule types, and inactive pipeline products. It also evaluates the competitive landscape and identifies potential opportunities across the global Eosinophilic Esophagitis treatment market. 

Download the Eosinophilic Esophagitis Pipeline Report @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Key Takeaways from the Eosinophilic Esophagitis Pipeline Report

• On May 27, 2026, Celldex Therapeutics announced a Phase II study evaluating the efficacy and safety of barzolvolimab in adults with Eosinophilic Esophagitis.

• On May 19, 2026, Regeneron Pharmaceuticals conducted a study evaluating dupilumab in children with active Eosinophilic Esophagitis, with a focus on disease-related feeding and nutritional challenges.

• On May 14, 2026, NexEos Diagnostics Inc. initiated a Phase II study evaluating the safety and exploratory diagnostic performance of NDX-3315 and NDX-3324 in healthy participants and patients with Eosinophilic Esophagitis.

• The Eosinophilic Esophagitis pipeline comprises 25+ active companies developing 30+ therapies, highlighting continued innovation in the treatment landscape.

• Leading Eosinophilic Esophagitis companies include Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma, and others.

• Promising Eosinophilic Esophagitis therapies include dupilumab, tezepelumab, NDX-3315, barzolvolimab, CC-93538, EP-104IAR, budesonide, and others.

Explore Eosinophilic Esophagitis Clinical Trials and Emerging Therapies @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is a chronic immune-mediated disorder characterized by the accumulation of eosinophils, a type of white blood cell, in the esophagus. The resulting inflammation can cause esophageal dysfunction and may lead to symptoms such as difficulty swallowing and problems with food passage.

The disease is associated with immune and antigen-mediated mechanisms and remains an area of significant therapeutic research. Increasing understanding of disease biology and the identification of new inflammatory pathways have encouraged pharmaceutical companies to investigate targeted treatment approaches.

Eosinophilic Esophagitis Emerging Drugs Profile

APT-1011: Ellodi Pharmaceuticals

APT-1011 is an investigational, once-daily oral disintegrating tablet designed to deliver fluticasone propionate directly to the esophageal mucosa while limiting exposure in the oral cavity.

Earlier clinical studies demonstrated reductions in esophageal eosinophil counts and endoscopic findings among adults with EoE. Following the FLUTE I and FLUTE II studies, APT-1011 has continued through clinical development. The therapy has received orphan drug designation from both the US FDA and the European Medicines Agency and is currently being evaluated in Phase III development for Eosinophilic Esophagitis.

IRL201104: Revolo Biotherapeutics

IRL201104 is an investigational linear peptide derived from the immune-regulatory protein Mycobacterium tuberculosis Chaperonin 60.1. The candidate is designed to modulate immune responses and has demonstrated immunoregulatory activity in preclinical models.

Following completion of Phase I development, IRL201104 is being evaluated in Phase II development for Eosinophilic Esophagitis and other Th2-associated allergic diseases. Its mechanism is focused on modulating macrophage responses and potentially promoting broader immune regulation.

AQ280: Aqilion

AQ280 is an oral, highly selective JAK1 inhibitor being developed for chronic inflammatory diseases, including Eosinophilic Esophagitis.

JAK1 plays an important role in inflammatory signaling pathways. By selectively inhibiting JAK1, AQ280 is being investigated for its potential to reduce inflammatory activity associated with EoE. The candidate is currently in Phase I development.

The Eosinophilic Esophagitis Pipeline Report Provides Insights Into

• Companies developing therapies for the treatment of Eosinophilic Esophagitis and their respective pipeline portfolios.

• Therapeutic candidates across early-, mid-, and late-stage development.

• Active and inactive Eosinophilic Esophagitis drug development programs.

• Pipeline therapies segmented by clinical stage, route of administration, target, mechanism of action, molecule type, and monotherapy or combination therapy.

• Key collaborations, licensing agreements, and financing activities supporting future development of Eosinophilic Esophagitis therapies.

• Emerging opportunities and potential changes in the competitive landscape.

Explore Eosinophilic Esophagitis Unmet Needs and Pipeline Analysis @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Eosinophilic Esophagitis Companies

Key companies involved in Eosinophilic Esophagitis drug development include:

Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma, and others.

Eosinophilic Esophagitis Pipeline by Route of Administration

The Eosinophilic Esophagitis pipeline report assesses therapies according to their route of administration, including:

• Intravenous

• Oral and other administration routes, where applicable

Eosinophilic Esophagitis Pipeline by Molecule Type

The pipeline includes multiple molecule types, such as:

• Peptides

• Proteins

• Small molecules

• Cell therapies

• Other therapeutic modalities

Discover Eosinophilic Esophagitis Market Drivers, Barriers, and Future Perspectives @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Scope of the Eosinophilic Esophagitis Pipeline Report

• Coverage: Global

• Key Companies: Ellodi Pharmaceuticals, Revolo Biotherapeutics, Aqilion, Bristol-Myers Squibb, EsoCap, Pfizer, Calypso Biotech, Serpin Pharma, Landos Biopharma, and others.

• Key Therapies: Dupilumab, Tezepelumab, NDX-3315, Barzolvolimab, CC-93538, EP-104IAR, Budesonide, and others.

• Therapeutic Assessment by Product Type: Monotherapy, combination therapy, and mono/combination therapy.

• Clinical Development Stages: Discovery, preclinical, Phase I, Phase II, and Phase III.

Explore Eosinophilic Esophagitis Emerging Drugs and Major Companies @ https://www.delveinsight.com/sample-request/eosinophilic-esophagitis-pipeline-insight?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Table of Contents

1. Introduction

2. Executive Summary

3. Eosinophilic Esophagitis: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Eosinophilic Esophagitis: DelveInsight’s Analytical Perspective

7. Late-Stage Products (Phase III)

8. APT-1011: Ellodi Pharmaceuticals

9. Drug Profiles in the Detailed Report

10. Mid-Stage Products (Phase II)

11. IRL201104: Revolo Biotherapeutics

12. Drug Profiles in the Detailed Report

13. Early-Stage Products (Phase I)

14. AQ280: Aqilion

15. Drug Profiles in the Detailed Report

16. Preclinical and Discovery-Stage Products

17. Drug Name: Company Name

18. Drug Profiles in the Detailed Report

19. Inactive Products

20. Eosinophilic Esophagitis Key Companies

21. Eosinophilic Esophagitis Key Products

22. Eosinophilic Esophagitis Unmet Needs

23. Eosinophilic Esophagitis Market Drivers and Barriers

24. Eosinophilic Esophagitis Future Perspectives and Conclusion

25. Eosinophilic Esophagitis Analyst Views

26. Eosinophilic Esophagitis Key Companies

27. Appendix

Related Reports

Eosinophilic Esophagitis Market Insight, Epidemiology, and Market Forecast – 2036

DelveInsight’s "Eosinophilic Esophagitis (EoE) Market Insight, Epidemiology, and Market Forecast – 2036" report delivers an in-depth understanding of the Eosinophilic Esophagitis historical and forecasted epidemiology as well as the Eosinophilic Esophagitis therapeutics market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Eosinophilic Esophagitis Epidemiology Forecast – 2036

DelveInsight’s “Eosinophilic Esophagitis (EoE) – Epidemiology Forecast – 2036” report delivers an in-depth understanding of Eosinophilic Esophagitis (EoE), historical and forecasted epidemiology of Eosinophilic Esophagitis (EoE) in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

About DelveInsight

DelveInsight is a healthcare-focused market research and consulting firm providing market intelligence and strategic insights across the life sciences and healthcare sectors. The company offers customized research solutions designed to help pharmaceutical and biotechnology companies make informed business decisions and identify emerging opportunities across evolving therapeutic landscapes.

Contact Us

Kanishk

info@delveinsight.com 

Idiopathic Membranous Nephropathy Market Projected to Reach USD 1 Billion by 2036, Driven by Expanding Therapeutic Options | DelveInsight

The idiopathic membranous nephropathy market is expected to grow steadily through 2036, supported by rising disease prevalence, improved diagnostic capabilities, advances in biomarker testing, and the development of targeted therapies such as SNP-ACTH (1-39) Gel, BRUKINSA (zanubrutinib), GAZYVA (obinutuzumab), MOR202 (felzartamab), povetacicept, Budoprutug, and others.

The recently published Idiopathic Membranous Nephropathy Market Insights report by DelveInsight provides a comprehensive assessment of current treatment practices, emerging therapies, epidemiology, market share, competitive landscape, and market forecasts from 2022 to 2036 across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Idiopathic Membranous Nephropathy Market Highlights

According to DelveInsight's analysis:

• The idiopathic membranous nephropathy market size in the 7MM was approximately USD 130 million in 2025.

• The United States represented the largest share of the IMN treatment market in 2025, accounting for approximately 60% of the 7MM market.

• Rituximab led the US IMN treatment market in 2025, although its market share is expected to decline through 2036 as newer therapies enter the treatment landscape.

• Approximately 69,500 diagnosed prevalent cases of idiopathic membranous nephropathy were reported across the 7MM in 2025.

• Key companies developing idiopathic membranous nephropathy drugs include Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Biogen, Vertex Pharmaceuticals Incorporated, Ono Pharmaceuticals, Walden Biosciences, AstraZeneca, Climb Bio, SynAct Pharma, Vera Therapeutics, Nkarta, Inc., and others.

• Key emerging therapies include SNP-ACTH (1-39) Gel, BRUKINSA (zanubrutinib), GAZYVA (obinutuzumab), MOR202 (felzartamab), ALPN-303 (povetacicept), WAL0921, ALXN1920, Budoprutug, Resomelagon (AP1189), Atacicept, NKX019, and others.

• Among the emerging therapies, Budoprutug, developed by Climb Bio, is in mid-stage development and is anticipated to receive approval in the United States by 2031, according to DelveInsight's forecast.

Discover which idiopathic membranous nephropathy therapies are expected to capture market share @ Idiopathic Membranous Nephropathy Market

Key Factors Driving the Idiopathic Membranous Nephropathy Market

Rising Prevalence of IMN

The diagnosed prevalent population of idiopathic membranous nephropathy is expected to increase during the forecast period. In 2025, approximately 70,000 diagnosed prevalent cases were estimated across the 7MM. An aging population, increased disease awareness, and improvements in diagnostic capabilities are expected to support continued identification of patients.

Advances in Anti-PLA2R Antibody Testing

The increasing availability of anti-phospholipase A2 receptor (PLA2R) antibody assays has changed the diagnostic approach to membranous nephropathy. The high specificity of anti-PLA2R antibodies has improved disease classification and may support more personalized disease monitoring and treatment decisions.

Development of Next-Generation Anti-CD20 Therapies

Although rituximab remains an important treatment option, treatment resistance and variable responses highlight the need for improved B-cell-targeting therapies. Obinutuzumab (GAZYVA) represents a next-generation anti-CD20 approach being investigated for potential improvements in efficacy and treatment outcomes.

Emergence of Novel Targeted Therapies

The IMN treatment landscape is expected to evolve significantly with the development of therapies targeting different disease pathways. Emerging candidates include SNP-ACTH (1-39) Gel, BRUKINSA, GAZYVA, MOR202, povetacicept, WAL0921, ALXN1920, Budoprutug, Resomelagon, Atacicept, and NKX019.

Idiopathic Membranous Nephropathy Market Analysis

The treatment landscape for idiopathic membranous nephropathy currently includes a combination of supportive care and immunosuppressive strategies.

Supportive management may include ACE inhibitors or angiotensin receptor blockers, statins, diuretics, and anticoagulants, depending on individual patient needs. Immunosuppressive approaches may include corticosteroids combined with alkylating agents, calcineurin inhibitors, rituximab, mycophenolate mofetil, and ACTH-based therapies.

Rituximab has become an important treatment option because of its ability to target B cells involved in the production of pathogenic autoantibodies, including anti-PLA2R antibodies. However, variability in response and the emergence of resistance create opportunities for therapies with alternative or complementary mechanisms.

The evolving pipeline reflects growing interest in therapies that target B-cell activation, survival, and autoantibody production. Povetacicept, Budoprutug, and SNP-ACTH (1-39) Gel are among the candidates expected to contribute to the future IMN treatment landscape.

Learn more about idiopathic membranous nephropathy treatment options @ Idiopathic Membranous Nephropathy Treatment Market

Idiopathic Membranous Nephropathy Competitive Landscape

The IMN pipeline includes therapies with diverse mechanisms of action and development strategies. Leading companies are investigating approaches designed to reduce pathogenic B-cell activity, modulate immune responses, and address the underlying mechanisms responsible for disease progression.

Cerium Pharmaceuticals' SNP-ACTH (1-39) Gel is a subcutaneous synthetic porcine ACTH therapy being developed to provide consistent ACTH dosing in primary membranous nephropathy. Following preclinical studies and a Phase I study in healthy volunteers, the therapy has advanced toward a Phase III randomized study designed to evaluate its potential against rituximab in patients with moderate- to high-risk disease.

Vertex Pharmaceuticals/Ono Pharmaceuticals' povetacicept is a dual BAFF and APRIL inhibitor designed to modulate B-cell activation, differentiation, and survival. Its engineered TACI domain is intended to provide enhanced binding affinity and potency. The therapy is being evaluated in clinical development for primary membranous nephropathy.

Other important pipeline candidates include:

• BRUKINSA (zanubrutinib) – BeiGene

• GAZYVA (obinutuzumab) – Hoffmann-La Roche

• MOR202 (felzartamab) – Biogen

• WAL0921 – Walden Biosciences

• ALXN1920 – AstraZeneca

• Budoprutug – Climb Bio

• Resomelagon (AP1189) – SynAct Pharma

• Atacicept – Vera Therapeutics

• NKX019 – Nkarta, Inc.

The anticipated introduction of these therapies could increase treatment options and reshape competition within the idiopathic membranous nephropathy market through 2036.

Explore emerging idiopathic membranous nephropathy therapies @ Idiopathic Membranous Nephropathy Clinical Trials

Recent Developments in the Idiopathic Membranous Nephropathy Market

• In January 2026, the European Medicines Agency granted PRIME designation to povetacicept for primary membranous nephropathy.

• In November 2025, the US FDA granted Fast Track Designation to povetacicept for primary membranous nephropathy.

• In November 2025, Vertex Pharmaceuticals Incorporated announced updated clinical data for povetacicept in IgA nephropathy and primary membranous nephropathy from the ongoing RUBY-3 trial.

• In November 2025, first-patient-in was achieved in the PrisMN Phase II trial, which is evaluating pharmacodynamic and preliminary efficacy outcomes in patients with primary membranous nephropathy.

• In October 2025, Climb Bio announced long-term follow-up data for Budoprutug from a Phase Ib study in primary membranous nephropathy, with data demonstrating sustained control of proteinuria in a small group of patients.

What Is Idiopathic Membranous Nephropathy?

Idiopathic membranous nephropathy is a chronic autoimmune kidney disorder characterized by the accumulation of immune complexes along the glomerular basement membrane. This can impair kidney filtration and may lead to nephrotic syndrome, proteinuria, low blood albumin levels, edema, and an increased risk of complications.

The disease is frequently associated with autoantibodies against PLA2R, although other antigens, including THSD7A, may also be involved. The clinical course varies among patients, ranging from spontaneous remission to progressive kidney function decline.

Idiopathic Membranous Nephropathy Epidemiology

DelveInsight's epidemiology analysis evaluates the historical and forecasted IMN patient population across the 7MM.

In the United States, late-onset disease represents a substantial proportion of the projected patient population. In 2025, approximately 20,000 PLA2R antigen-specific cases and 800 THSD7A antigen-specific cases were estimated.

The epidemiology analysis covers:

• Total diagnosed prevalent cases of IMN

• Antigen-specific cases of IMN

• Treated cases of IMN

Access the complete epidemiology assessment @ Idiopathic Membranous Nephropathy Epidemiology Forecast 

Idiopathic Membranous Nephropathy Market Report Metrics

• Study Period: 2022–2036

• Geographic Coverage: 7MM, including the US, EU4, the UK, and Japan

• Market CAGR: 0.4%

• Market Size in 2025: USD 130 million

• Key Companies: Cerium Pharmaceuticals, BeiGene, Hoffmann-La Roche, Biogen, Vertex Pharmaceuticals, Ono Pharmaceuticals, Walden Biosciences, AstraZeneca, Climb Bio, SynAct Pharma, Vera Therapeutics, Nkarta, and others

• Key Therapies: SNP-ACTH (1-39) Gel, BRUKINSA, GAZYVA, MOR202, povetacicept, WAL0921, ALXN1920, Budoprutug, Resomelagon, Atacicept, NKX019, and others

Scope of the Idiopathic Membranous Nephropathy Market Report

The report provides comprehensive coverage of:

• Therapeutic Assessment: Current marketed and emerging IMN therapies

• Market Dynamics: Key market drivers, barriers, forecast assumptions, and emerging therapy assessment

• Competitive Intelligence: Competitive landscape, SWOT analysis, and market entry strategies

• Unmet Needs: Assessment of treatment gaps and opportunities for innovation

• KOL Insights: Expert perspectives on disease management and emerging therapies

• Market Access and Reimbursement: Regional assessment across the US, EU4, UK, and Japan

Discover more about IMN drugs in development @ Idiopathic Membranous Nephropathy Market Analysis

Table of Contents

1. Idiopathic Membranous Nephropathy Market Key Insights

2. Idiopathic Membranous Nephropathy Market Report Introduction

3. IMN Market Overview at a Glance

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

8. Treatment and Management

9. Epidemiology and Patient Population

10. Idiopathic Membranous Nephropathy Patient Journey

11. Emerging Idiopathic Membranous Nephropathy Therapies

12. Idiopathic Membranous Nephropathy Market Analysis

13. KOL Views on IMN

14. Idiopathic Membranous Nephropathy Market SWOT Analysis

15. Idiopathic Membranous Nephropathy Market Unmet Needs

16. Idiopathic Membranous Nephropathy Market Access and Reimbursement

17. Bibliography

18. Idiopathic Membranous Nephropathy Market Report Methodology

Related Reports

Idiopathic Membranous Nephropathy Epidemiology Forecast – 2036
Provides an in-depth assessment of historical and forecasted IMN epidemiology across the 7MM.

IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034
Provides insights into market trends, epidemiology, individual therapy market shares, and the competitive landscape.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive end-to-end solutions to help pharmaceutical, biotechnology, and healthcare organizations make informed strategic decisions.

DelveInsight offers access to healthcare and pharmaceutical market intelligence through its subscription-based platform, PharmDelve.

Contact Us

Kanishk

info@delveinsight.com 

Tenosynovial Giant Cell Tumors Market to Show Significant Growth by 2034 as CSF1R-Targeted Therapies Drive the Next Wave | DelveInsight

The tenosynovial giant cell tumors (TGCT) market is expected to witness significant growth through 2034, supported by rising disease awareness, improved diagnostic capabilities, advanced imaging techniques, increasing adoption of targeted therapies, and continued clinical development of novel treatments. Emerging therapies such as emactuzumab, pimicotinib, and AMB-051 are expected to expand treatment options for patients with localized and diffuse TGCT.

DelveInsight's Tenosynovial Giant Cell Tumors Market Insights report provides a comprehensive assessment of current treatment practices, emerging TGCT drugs, individual therapy market shares, epidemiology, and forecasted market trends from 2020 to 2034 across the 7MM, including the United States, EU4, the United Kingdom, and Japan.

Tenosynovial Giant Cell Tumors Market Summary

• The tenosynovial giant cell tumors treatment market is expected to grow positively through 2034 across the leading markets.

• The United States represents the largest TGCT market compared with the EU4, the UK, and Japan.

• According to DelveInsight's analysis, there were more than 630,000 prevalent TGCT cases in the 7MM in 2024, with the patient population projected to increase through 2034.

• Key TGCT companies, including SynOx Therapeutics, Abbisko Therapeutics, AmMax Bio, Daiichi Sankyo, and Deciphera Pharmaceuticals, are developing innovative therapies.

• Promising therapies in the TGCT pipeline include Emactuzumab, Pimicotinib, AMB-05X, and other targeted agents.

• The growing development of CSF1R-targeted therapies is expected to reshape the TGCT treatment landscape by providing alternatives to repeated surgical intervention.

Discover which TGCT medications are expected to capture market share @ Tenosynovial Giant Cell Tumors Market

Sadaf Javed, Manager of Forecasting and Analytics at DelveInsight, commented that advancements in research, new diagnostic techniques, and improved diagnostic parameters are expected to increase TGCT diagnosis and potentially improve patient prognosis.

Key Factors Driving the Growth of the Tenosynovial Giant Cell Tumors Market

Rising TGCT Cases

In 2024, the United States had approximately 230,000 localized TGCT cases and nearly 60,000 diffuse TGCT cases. These patient numbers are expected to increase during the forecast period.

Improved access to high-resolution imaging, increased clinical awareness, earlier diagnosis, and better patient referral pathways are expected to contribute to the identification of additional cases. Greater use of comprehensive disease registries may also improve the understanding of the TGCT patient population.

Advancements in Targeted Therapies

The TGCT treatment landscape is moving beyond conventional surgical management toward targeted molecular therapies. CSF1R inhibitors and kinase inhibitors, including agents such as pexidartinib and vimseltinib, have expanded systemic treatment possibilities.

These therapies may be particularly important for patients with diffuse or recurrent disease who are not suitable candidates for surgery or who may experience significant morbidity from repeated surgical procedures.

Improved Diagnostic Techniques and Disease Awareness

Advancements in diagnostic imaging, particularly MRI, have strengthened the ability to identify TGCT lesions and characterize disease involvement.

Greater awareness among healthcare professionals and patients may support earlier diagnosis, referral to specialists, and appropriate treatment selection.

Emerging CSF1R-Targeted Therapies

Several companies are developing therapies designed to interfere with the CSF1/CSF1R pathway, which plays an important role in the biology of TGCT.

Notable emerging therapies include:

• Emactuzumab from SynOx Therapeutics

• Pimicotinib (ABSK021) from Abbisko Therapeutics/Merck

• AMB-051 (AMB-05X) from AmMax Bio

These therapies are being investigated as potential non-surgical options, particularly for patients with diffuse, recurrent, or difficult-to-treat TGCT.

Tenosynovial Giant Cell Tumors Market Analysis

Surgical resection remains an important treatment option for TGCT. However, diffuse TGCT (DTGCT) can be difficult to completely remove and is associated with a substantial risk of recurrence.

Repeated surgeries may negatively affect joint function and quality of life and can increase the risk of complications and secondary joint damage.

Systemic therapies targeting the CSF1/CSF1R pathway have therefore become an important area of development.

Earlier approaches included less-selective tyrosine kinase inhibitors such as imatinib and nilotinib, while more selective CSF1R-directed therapies have subsequently expanded the treatment landscape.

TURALIO (pexidartinib) became the first FDA-approved systemic therapy for patients with symptomatic TGCT who are not candidates for surgery. However, its use is associated with concerns regarding hepatotoxicity.

ROMVIMZA (vimseltinib) provides another systemic treatment option and further strengthens the targeted therapy landscape.

Additional investigational therapies such as emactuzumab, pimicotinib, and AMB-051 could further increase competition and treatment options during the forecast period.

Learn more about TGCT treatment options @ Tenosynovial Giant Cell Tumors Treatment Market

Tenosynovial Giant Cell Tumors Competitive Landscape

The TGCT competitive landscape is expected to become increasingly active as companies advance targeted therapies designed to address the underlying biology of the disease.

SynOx Therapeutics' Emactuzumab

Emactuzumab is a highly selective monoclonal antibody targeting CSF1R. By interfering with CSF1R signaling, the therapy is designed to reduce macrophage-related activity associated with TGCT.

SynOx Therapeutics has been developing emactuzumab as a potential treatment for patients who are unsuitable for surgery or unlikely to benefit from surgical intervention.

Abbisko Therapeutics/Merck's Pimicotinib

Pimicotinib (ABSK021) is an oral, highly selective CSF1R inhibitor under development for TGCT.

The therapy works by inhibiting CSF1R signaling and reducing macrophage accumulation associated with the disease. Its development could provide an additional systemic treatment option for patients with TGCT.

AmMax Bio's AMB-051

AMB-051 (AMB-05X) is a monoclonal antibody targeting CSF1R and is being investigated for localized and diffuse TGCT.

The therapy has progressed through clinical development, with the company investigating its potential to address inflammatory and fibrotic processes associated with TGCT.

AMB-05X received FDA Fast Track Designation in September 2022 and EMA PRIME designation in January 2023, supporting its continued development.

The expected introduction of these emerging therapies could significantly influence the TGCT market by increasing treatment options and competition among targeted therapies.

Recent Developments in the Tenosynovial Giant Cell Tumors Market

• In December 2025, pimicotinib received approval in China as a systemic treatment for TGCT, representing its first regulatory approval worldwide.

• In September 2025, the European Commission granted marketing authorization for ROMVIMZA (vimseltinib) for TGCT.

• In August 2025, SynOx Therapeutics completed patient enrollment in the TANGENT Phase III study evaluating emactuzumab in TGCT patients who were unsuitable for surgery or unlikely to benefit from surgery.

• In April 2025, the US FDA granted Fast Track Designation to emactuzumab for TGCT.

• In March 2025, Abbisko Therapeutics reported that Merck exercised its global commercialization option for pimicotinib, involving an USD 85 million option exercise fee under the existing licensing agreement.

What are Tenosynovial Giant Cell Tumors?

Tenosynovial giant cell tumors (TGCTs) are rare, generally benign tumors that develop in the synovial tissue surrounding joints, tendon sheaths, and bursae.

TGCTs are broadly classified into localized TGCT and diffuse TGCT.

Localized TGCT generally affects a limited area around a joint, whereas diffuse TGCT can involve a larger portion of the synovium and may cause more extensive joint-related problems.

Common manifestations can include:

• Joint swelling

• Pain

• Stiffness

• Reduced mobility

• Recurrent disease following treatment

Although TGCT is generally benign, diffuse disease can be associated with significant morbidity and may require repeated treatment.

Tenosynovial Giant Cell Tumors Epidemiology Segmentation

The TGCT epidemiology analysis provides insights into the historical and forecasted patient population across the 7MM.

In 2024, localized TGCT represented the predominant growth pattern across the 7MM, while Japan reported approximately 79% of prevalent TGCT cases as localized.

The TGCT epidemiology analysis covers:

• Prevalent Cases of TGCT

• Growth Pattern-specific Prevalent Cases of TGCT

• Gender-specific Prevalent Cases of Localized TGCT

• Gender-specific Prevalent Cases of Diffuse TGCT

• Tumor Location-specific Prevalent Cases of Localized TGCT

• Tumor Location-specific Prevalent Cases of Diffuse TGCT

• Total Treated Cases of TGCT

Download the report to understand TGCT management @ Tenosynovial Giant Cell Tumors Treatment Options

Tenosynovial Giant Cell Tumors Market Report Metrics

• Study Period: 2020–2034

• Market Coverage: 7MM

• Geographic Coverage: US, EU4, UK, and Japan

• 7MM Prevalent Cases in 2024: More than 630,000

• Key Companies: SynOx Therapeutics, Abbisko Therapeutics, AmMax Bio, Daiichi Sankyo, Deciphera Pharmaceuticals, and others

• Key Therapies: Emactuzumab, Pimicotinib, AMB-05X, TURALIO, ROMVIMZA, and others

Scope of the Tenosynovial Giant Cell Tumors Market Report

• TGCT Therapeutic Assessment: Analysis of current marketed and emerging therapies.

• TGCT Market Dynamics: Assessment of emerging therapies and their potential impact on the market.

• Competitive Intelligence Analysis: SWOT analysis and market entry strategies.

• Unmet Needs: Assessment of gaps in current treatment options.

• KOL Views: Expert perspectives on the evolving TGCT treatment landscape.

• Market Access and Reimbursement: Analysis of access and reimbursement scenarios across major markets.

Discover more about TGCT drugs in development @ Tenosynovial Giant Cell Tumors Clinical Trials

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

5. Epidemiology and Market Forecast Methodology

6. Tenosynovial Giant Cell Tumor (TGCT) Market Overview at a Glance

7. Disease Background and Overview

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Drugs

11. Emerging Drugs

12. Tenosynovial Giant Cell Tumour: Seven Major Market Analysis

13. Unmet Needs

14. SWOT Analysis

15. KOL Views

16. Market Access and Reimbursement

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

Key Market Sections Include

Disease Background and Overview

• Introduction of TGCT

• Etiology

• Molecular biology

• Classification

• Clinical features

• Pathogenesis

• Biomarkers

• Diagnosis

• Treatment

Epidemiology

• Prevalent cases

• Growth pattern-specific cases

• Gender-specific localized TGCT cases

• Gender-specific diffuse TGCT cases

• Tumor localization

• Treated cases

Marketed Therapies

• TURALIO (pexidartinib)

• ROMVIMZA (vimseltinib)

• Other marketed therapies

Emerging Therapies

• Emactuzumab

• Pimicotinib

• AMB-051

• Other pipeline therapies

Market Analysis

• 7MM market size

• US market size

• EU4 and UK market size

• Japan market size

• Therapy-specific market shares

• Market forecast assumptions

• Attribute analysis

Additional Analysis

• Market access and reimbursement

• KOL views

• SWOT analysis

• Unmet needs

• Competitive landscape

• Market methodology

Related Reports

Tenosynovial Giant Cell Tumors Epidemiology Forecast – 2034

This report provides an in-depth assessment of historical and forecasted TGCT epidemiology across the 7MM, including the United States, EU4, the United Kingdom, and Japan.

Tenosynovial Giant Cell Tumors Pipeline Insight – 2026

This report evaluates the TGCT pipeline landscape, including clinical and non-clinical products and key companies such as AmMax Bio, Deciphera Pharmaceuticals, SynOx Therapeutics, Abbisko Therapeutics, Hutchison Medipharma, and Elixiron Immunotherapeutics, among others.

About DelveInsight

DelveInsight is a business research and consulting company focused on the life sciences industry. It provides market research, competitive intelligence, epidemiology, and consulting solutions to help pharmaceutical and biotechnology companies understand evolving markets and make informed business decisions.

Contact Us

Kanishk

info@delveinsight.com 

H. pylori Infections Market in the 6MM to Grow at a CAGR of 9.4% Through 2036, Driven by Emerging Therapies and Advanced Treatment Strategies | DelveInsight

The H. pylori infections market is poised for significant growth as treatment approaches evolve toward optimized combination therapies, including triple and quadruple regimens, bismuth-based therapies, and emerging treatments such as Rifasutenizol (TNP-2198), Linaprazan glurate, and Tegoprazan (RQ-00000004).

According to the latest H. pylori Infections Market Insights report by DelveInsight, the 6MM market, comprising the United States, EU4 countries (Germany, France, Italy, and Spain), and the United Kingdom, was valued at approximately USD 270 million in 2025 and is projected to expand at a CAGR of 9.4% from 2026 to 2036.

H. pylori Infections Market Key Highlights

• The H. pylori infections market size in the 6MM was approximately USD 270 million in 2025.

• The United States represented around 85% of the total 6MM market in 2025.

• Vonoprazan (VOQUEZNA Dual & Triple Pak) is expected to capture the largest market share in the United States by 2036.

• Approximately 147 million diagnosed prevalent cases of H. pylori infection were estimated across the 6MM in 2025.

• The United States accounted for approximately 57 million diagnosed prevalent cases in 2025.

• Key companies developing emerging H. pylori therapies include TenNor Therapeutics, Cinclus Pharma, RaQualia Pharma, HK-inno.N, and Braintree (Sebela Pharmaceuticals).

• Key pipeline therapies include Rifasutenizol (TNP-2198), Linaprazan glurate, and Tegoprazan/RQ-00000004.

Discover the H. pylori infections market forecast through 2036: H. pylori Infections Market Sample Request

Key Factors Driving the H. pylori Infections Market

Rising H. pylori Prevalence

The growing number of diagnosed H. pylori infections is expected to support market expansion. According to DelveInsight estimates, approximately 57 million diagnosed prevalent cases were reported in the United States in 2025. Improvements in diagnostic capabilities, disease awareness, and public health initiatives are expected to contribute to further increases in diagnosed cases through 2036.

Growing Role of Molecular Diagnostics

Molecular diagnostic approaches such as RT-PCR can provide rapid and sensitive detection while helping identify antibiotic resistance. These capabilities may support more personalized treatment selection and improve eradication strategies.

Increasing Use of Bismuth-Based Regimens

Bismuth-containing treatment regimens remain important options for patients with antibiotic-resistant H. pylori infection. Their incorporation into combination therapies can improve eradication outcomes, particularly against strains resistant to commonly used antibiotics.

Growing Demand for Convenient Treatment Regimens

Pre-packaged therapies such as VOQUEZNA and TALICIA offer simplified treatment approaches compared with regimens requiring patients to manage multiple individual medications. Convenience and adherence are expected to remain important considerations in treatment selection.

Emergence of Novel Therapies

The H. pylori treatment landscape is expected to evolve as pipeline candidates progress through clinical development. Key emerging therapies include Rifasutenizol, Linaprazan glurate, and Tegoprazan/RQ-00000004, among others.

H. pylori Infections Market Analysis

The H. pylori treatment landscape continues to balance established therapies with newer approaches designed to improve efficacy, tolerability, and treatment convenience.

• Bismuth-based and concomitant quadruple therapies remain important empiric treatment options, with clinical studies reporting eradication rates above 90% for certain regimens.

• Concomitant quadruple therapy may increase antibiotic exposure, raising considerations around antimicrobial stewardship.

• VOQUEZNA and TALICIA offer pre-packaged treatment options that can simplify dosing.

• Traditional bismuth-containing regimens can involve substantial pill burdens, potentially affecting treatment adherence.

• Vonoprazan has extensive experience in Japan and is also available in the United States, while regulatory availability varies across European markets.

• TALICIA, a rifabutin-based triple therapy, is FDA-approved in the United States, while its European regulatory status differs by market.

• The emerging pipeline remains relatively limited, creating an opportunity for differentiated therapies that can address antibiotic resistance and improve eradication rates.

H. pylori Infections Competitive Landscape

The competitive landscape includes established therapies as well as a small group of emerging candidates targeting unmet needs in H. pylori eradication.

TenNor Therapeutics' Rifasutenizol (TNP-2198)

Rifasutenizol is an investigational oral antibacterial agent designed to combine rifamycin and nitroimidazole activity within a single molecule. The therapy is being developed for H. pylori infection, including antibiotic-resistant infections.

According to DelveInsight analysis, the therapy's dual mechanism and clinical development progress could differentiate it from conventional multi-drug regimens. Its development is particularly relevant given the growing challenge of antibiotic resistance.

Cinclus Pharma's Linaprazan Glurate

Linaprazan glurate is an investigational next-generation potassium-competitive acid blocker (P-CAB). As a prodrug of linaprazan, it is designed to provide rapid and sustained gastric acid suppression.

The therapy is being evaluated for gastrointestinal conditions and may have potential applications within H. pylori treatment combinations. Its prolonged acid suppression could provide an alternative to conventional proton pump inhibitor-based approaches.

RaQualia Pharma/HK inno.N/Sebela Pharmaceuticals' Tegoprazan

Tegoprazan (RQ-00000004) is a P-CAB designed to suppress gastric acid secretion. Compared with traditional proton pump inhibitors, P-CABs can provide rapid and sustained acid suppression.

Its development for H. pylori infection could further expand the use of P-CAB-based treatment strategies and introduce additional competition into the market.

Discover more about the emerging H. pylori therapies pipeline: H. pylori Infections Drugs

Recent Developments in the H. pylori Infections Market

• January 2026: RedHill Biopharma updated its ongoing UK Marketing Authorisation Application for TALICIA for the treatment of H. pylori infection under the UK's MHRA International Recognition Procedure.

• November 2025: Cinclus Pharma announced plans to initiate clinical studies of linaprazan glurate in H. pylori infection, with results expected in 2027 and potential regulatory submissions thereafter.

• August 2025: The New Drug Application for rifasutenizol capsules for H. pylori infection was accepted by China's National Medical Products Administration.

• June 2025: Cinclus Pharma announced that the US FDA and EMA had granted waivers from pediatric study requirements for linaprazan glurate in H. pylori infection.

• May 2025: TenNor Therapeutics presented Phase III EVEREST-HP trial results evaluating rifasutenizol as a first-line treatment for H. pylori infection at Digestive Disease Week 2025.

What Are H. pylori Infections?

Helicobacter pylori (H. pylori) is a bacterium that can colonize the stomach lining and contribute to gastrointestinal disorders. While many infected individuals may not experience symptoms, H. pylori infection can be associated with gastritis, peptic ulcers, and an increased risk of gastric cancer.

Diagnosis can involve breath, stool, blood, or endoscopic testing, depending on the clinical setting. Treatment generally involves combinations of antibiotics and acid-suppressing medicines designed to eradicate the infection.

H. pylori Infections Epidemiology

DelveInsight's epidemiology analysis provides historical and forecast estimates of the H. pylori patient population across the United States, EU4, and the United Kingdom.

The report covers:

• Total diagnosed prevalent cases of H. pylori infection

• Age-specific diagnosed prevalent cases

• Gender-specific diagnosed prevalent cases

• Total treated cases

The total diagnosed prevalent cases across the 6MM were estimated at approximately 147 million in 2025, while the United States accounted for approximately 57 million diagnosed prevalent cases.

H. pylori Infections Market Report Metrics

• Study Period: 2022–2036

• Forecast Period: 2026–2036

• Geographic Coverage: 6MM

• 6MM Markets: United States, EU4, and United Kingdom

• Market Size in 2025: USD 270 Million

• Market CAGR: 9.4%

• Key Companies: TenNor Therapeutics, Cinclus Pharma, RaQualia Pharma, HK-inno.N, Braintree (Sebela Pharmaceuticals), RedHill BioPharma, Cumberland Pharmaceuticals, Phathom Pharmaceuticals, and others

• Key Therapies: Rifasutenizol (TNP-2198), Linaprazan Glurate, Tegoprazan/RQ-00000004, TALICIA, VOQUEZNA TRIPLE, VOQUEZNA DUAL, and others

Scope of the H. pylori Infections Market Report

The report provides comprehensive coverage of:

• Therapeutic Assessment: Current marketed and emerging H. pylori therapies

• Market Dynamics: Key market drivers, barriers, forecast assumptions, and market outlook

• Competitive Intelligence: Competitive landscape, SWOT analysis, and market entry strategies

• Epidemiology: Historical and forecast patient population across major markets

• Unmet Needs: Key gaps in current treatment approaches

• KOL and Analyst Insights: Expert perspectives on the evolving treatment landscape

• Market Access and Reimbursement: Assessment across the United States, EU4, and the United Kingdom

Explore the H. pylori infections market analysis: H. pylori Infections Market Analysis

Related Reports

H. pylori Infections Pipeline Insight

H. pylori Infections Pipeline Insight – 2026 provides an assessment of the H. pylori clinical development landscape, including pipeline drug profiles, clinical and non-clinical programs, and key companies.

Bacterial Vaginosis Market

Bacterial Vaginosis Market Insights, Epidemiology, and Market Forecast – 2034 analyzes the disease landscape, epidemiology, market trends, and competitive environment across major markets.

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market

Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia Market Insights, Epidemiology, and Market Forecast – 2034 provides analysis of the HABP/VABP market, treatment landscape, epidemiology, and key companies.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides comprehensive market intelligence, epidemiology, competitive intelligence, and consulting solutions to support strategic decision-making across the pharmaceutical and healthcare sectors.

Through its subscription-based platform, PharmDelve, DelveInsight provides access to a broad portfolio of healthcare and pharmaceutical market research reports.

Contact Us

Kanishk

info@delveinsight.com 

Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight

The generalized myasthenia gravis treatment pipeline features several promising late-stage candidates, including IMVT-1402 (Immunovant/Roivant Sciences), Descartes-08 (Cartesian Therapeutics), Remibrutinib (Novartis), FABHALTA (Iptacopan) (Novartis), Gefurulimab (Alexion AstraZeneca Rare Disease), MAVENCLAD (Cladribine) (Merck KGaA), Telitacicept (RemeGen), and Pozelimab + Cemdisiran (Regeneron Pharmaceuticals), along with other emerging therapies advancing through clinical development.

The generalized myasthenia gravis treatment landscape is entering a period of significant transformation as next-generation FcRn, complement, BTK, B-cell-targeted, and cell-based therapies progress through late-stage development. These emerging approaches could expand treatment options and address important unmet needs for patients with generalized myasthenia gravis.

Generalized myasthenia gravis (gMG) accounts for nearly 70% of all myasthenia gravis cases and is primarily associated with autoantibodies targeting the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK), which are important components of neuromuscular signaling.

Treatment has evolved from conventional cholinesterase inhibitors and immunosuppressants toward targeted therapies, including ULTOMIRIS and VYVGART, as well as VYVGART HYTRULO/VYVDURA. Acute interventions such as plasmapheresis and intravenous immunoglobulin (IVIG) remain important for severe disease, while thymectomy continues to have a role in selected patients.

According to DelveInsight's analysis, the gMG market across the 7MM was valued at USD 5.9 billion in 2025 and is projected to grow at a CAGR of 9.1% through 2036. Market expansion is expected to be supported by increasing biologic adoption, improvements in diagnosis, and broader access to advanced treatments.

Discover the Generalized Myasthenia Gravis Market Forecast @ https://www.delveinsight.com/sample-request/generalized-myasthenia-gravis-gmg-market?utm_source=apac&utm_medium=promotion&utm_campaign=kkpr

Despite significant therapeutic progress, important unmet needs remain, particularly around rapid disease control, sustained disease management, and treatment options for patients who remain inadequately controlled or refractory to existing therapies. These needs are encouraging the development of therapies designed to provide faster onset, durable efficacy, convenient administration, and differentiated safety profiles.

Below are eight late-stage therapies that could influence the future generalized myasthenia gravis treatment landscape.

Immunovant/Roivant Sciences’ IMVT-1402

FcRn Antagonist

IMVT-1402 is a next-generation, subcutaneously administered anti-FcRn monoclonal antibody being developed by Immunovant for IgG-mediated autoimmune diseases. The therapy is designed to reduce pathogenic IgG levels while maintaining normal albumin and cholesterol levels, potentially addressing some safety considerations associated with earlier FcRn inhibitors.

As Immunovant's key development asset, IMVT-1402 is being evaluated across autoimmune indications, including myasthenia gravis. The company has elected not to pursue regulatory approval for batoclimab in myasthenia gravis and is instead using learnings from its development program to support the advancement of IMVT-1402.

RemeGen/Vor Bio’s Telitacicept

BLyS/APRIL Dual-Target Fusion Protein

Telitacicept (RC18) is a fusion protein designed to inhibit key pathways involved in B-cell activity and autoantibody production. It combines the transmembrane activator and CAML interactor (TACI) receptor with the Fc region of human IgG, enabling simultaneous inhibition of BLyS and APRIL.

By targeting these two cytokines, telitacicept is designed to reduce B-cell survival and abnormal autoantibody production. The therapy is undergoing Phase III clinical development in generalized myasthenia gravis and has already received approval in China for the indication.

Its dual-target mechanism distinguishes telitacicept from therapies that act on a single pathway and could provide an additional treatment option for patients with gMG.

Explore what are the emerging therapies in gMG and their market impact @ Emerging Therapies in gMG Market

Novartis’ FABHALTA (Iptacopan)

Complement Factor B Inhibitor

Iptacopan (LNP023), marketed as FABHALTA, is an orally administered small-molecule inhibitor of Factor B, a key component of the alternative complement pathway. By selectively inhibiting Factor B, iptacopan is designed to reduce downstream complement activation and potentially limit complement-mediated tissue injury.

The therapy is already approved for other indications, while its potential role in generalized myasthenia gravis continues to be evaluated. Novartis is expected to submit Phase III data for gMG by 2027.

Alexion AstraZeneca Rare Disease’s Gefurulimab

C5 Inhibitor

Gefurulimab (ALXN-1720) is an investigational humanized bispecific VHH antibody designed to bind complement protein C5 and albumin. The therapy is being developed for generalized myasthenia gravis and proteinuria and has been optimized for subcutaneous administration.

Through its C5-binding component, gefurulimab is designed to inhibit terminal complement pathway activation. Its albumin-binding component is intended to extend the molecule's half-life, supporting sustained therapeutic activity.

The therapy has advanced into the regulatory development stage, positioning gefurulimab as a potential future competitor within the complement inhibitor segment of the gMG treatment market.

To know more about emerging FcRn therapies to reshape gMG treatment landscape, visit @ Generalized Myasthenia Gravis Medication

Regeneron Pharmaceuticals’ Pozelimab + Cemdisiran

Complement C5 Inhibition

Pozelimab + cemdisiran, also referred to as Poze-Cemdi, represents a dual-mechanism approach to complement C5 inhibition.

Pozelimab is a fully human monoclonal antibody that directly inhibits C5, while cemdisiran is an investigational small interfering RNA therapy designed to reduce circulating C5 production. The combination is intended to provide complementary inhibition of the C5 pathway.

Both components are being evaluated across complement-mediated diseases, including myasthenia gravis. If successful, this approach could offer another mechanism for controlling complement-driven disease activity in gMG.

Novartis’ Remibrutinib

BTK Inhibitor

Remibrutinib (LOU064) is an investigational, highly selective, covalent oral Bruton’s tyrosine kinase (BTK) inhibitor. By targeting BTK signaling, the therapy is designed to modulate B-cell activity and downstream immune responses involved in the pathophysiology of generalized myasthenia gravis.

Remibrutinib is currently in Phase III clinical development for gMG. Its oral formulation could provide an administration advantage compared with intravenous or subcutaneous therapies.

According to Ramandeep Singh, Senior Consultant of Forecasting at DelveInsight, remibrutinib's late-stage development and oral dosing could provide differentiation in an increasingly competitive gMG market. However, competition from FcRn inhibitors, complement inhibitors, and other targeted therapies could influence its future market positioning.

Find out more about which drugs will gain maximum market share in gMG @ Generalized Myasthenia Gravis Drug Treatment

Cartesian Therapeutics’ Descartes-08

RNA CAR T-Cell Therapy

Descartes-08 is an RNA-engineered CAR T-cell therapy being developed for myasthenia gravis and other autoimmune diseases. Unlike conventional DNA-based CAR T-cell approaches, its RNA-based platform is designed to provide transient cellular engineering without genomic integration.

The therapy uses an autologous approach in which a patient's own cells are collected, engineered using RNA, and subsequently reinfused. The treatment regimen includes six weekly infusions.

The program has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations, while its Phase III AURORA trial is progressing under an FDA Special Protocol Assessment.

An Assistant Project Manager in Forecasting at DelveInsight noted that Descartes-08 could represent an important development in autoimmune cell therapy, particularly if clinical studies demonstrate durable disease control with an acceptable safety profile.

Merck KGaA’s MAVENCLAD (Cladribine)

B- and T-Lymphocyte-Targeted Therapy

Cladribine, marketed as MAVENCLAD, is an oral treatment candidate being investigated for generalized myasthenia gravis. The therapy is designed to reduce B and T lymphocytes, immune cells that contribute to abnormal autoantibody production and inflammation.

Its short-course oral administration could potentially reduce treatment burden compared with therapies requiring frequent parenteral administration.

Discover more about gMG drugs in development @ Generalized Myasthenia Gravis Clinical Trials

The gMG Treatment Landscape Is Becoming Increasingly Competitive

The development of these eight therapies highlights the diversification of the generalized myasthenia gravis pipeline. Rather than relying predominantly on conventional immunosuppression, developers are pursuing multiple biological pathways, including FcRn, complement, BTK, BLyS/APRIL, and cellular immunotherapy.

The expanding pipeline could increase competition across efficacy, safety, route of administration, durability, dosing frequency, and overall treatment burden. As late-stage clinical data become available, these factors will be important in determining which therapies can achieve meaningful differentiation and market uptake.

The anticipated entry of additional targeted therapies could also influence treatment sequencing and physician preferences, potentially creating new opportunities for pharmaceutical companies while giving patients and healthcare providers more therapeutic choices.

The Generalized Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast – 2036 report provides an in-depth assessment of disease epidemiology, treatment trends, market dynamics, emerging therapies, and competitive activity across the major markets.

The report covers key companies including UCB, Johnson & Johnson, Amgen, Immunovant, Roivant Sciences, Cartesian Therapeutics, Novartis, Alexion AstraZeneca Rare Disease, Merck KGaA, RemeGen, Regeneron Pharmaceuticals, argenx, Kyverna Therapeutics, NMD Pharma, Dianthus Therapeutics, Cabaletta Bio, COUR Pharmaceutical, ImmunAbs, Flerie, Toleranzia, Arcellx, Bristol Myers Squibb, Ahead Therapeutics, Biohaven, and others.

About DelveInsight

DelveInsight is a leading business consulting and market research firm focused exclusively on the life sciences industry. The company provides market intelligence, epidemiology, competitive intelligence, pipeline assessment, and strategic consulting solutions to help pharmaceutical and biotechnology companies make informed business decisions.

For access to healthcare and pharmaceutical market research reports, DelveInsight also provides its subscription-based platform, PharmDelve.

Contact Us

Kanishk

info@delveinsight.com